Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Clinical Cancer Research
Published October 5, 2026
Long-term outcomes of modified-intensity lenalidomide, bortezomib and dexamethasone (RVD-lite) in...
October 6, 2026
Medspoke
Medspoke
Clinical Cancer Research
Published October 5, 2026
00:00
--:--
Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancer...
October 6, 2026
Share
Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib.
https://www.medspoke.co/channel_journal?id=686&tap_id=15105
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
Clinical Cancer Research
Published October 5, 2026
Progress in Clinical Care and Research for Li-Fraumeni Syndrome: Perspectives from the 7th Li-Fra...
October 6, 2026
Why are you reporting this TALK?